Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
226.85 (1y: +72%)
Market Cap 54.12 B P/E(ttm) 36.00
Enterprise Value 54.37 B P/B 7.70
BIIB- NAS (USA)
Biogen Idec Inc
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$226.85
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 1.495
BIIB's Cash to Debt is ranked lower than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 1.495 )
BIIB' s 10-Year Cash to Debt Range
Min: 0.25   Max: 15.36
Current: 1.5
0.25
15.36
Equity to Asset 0.408
BIIB's Equity to Asset is ranked lower than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. BIIB: 0.408 )
BIIB' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.79
Current: 0.41
0.22
0.79
Interest Coverage 265.1
BIIB's Interest Coverage is ranked lower than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 265.1 )
BIIB' s 10-Year Interest Coverage Range
Min: 91   Max: No Debt
Current: 265.1
F-Score: 5
Z-Score: 13.83
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 33.60
BIIB's Operating margin (%) is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. BIIB: 33.60 )
BIIB' s 10-Year Operating margin (%) Range
Min: -128   Max: 39.8
Current: 33.6
-128
39.8
Net-margin (%) 25
BIIB's Net-margin (%) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. BIIB: 25 )
BIIB' s 10-Year Net-margin (%) Range
Min: -128.8   Max: 36
Current: 25
-128.8
36
ROE (%) 19.8
BIIB's ROE (%) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. BIIB: 19.8 )
BIIB' s 10-Year ROE (%) Range
Min: -12.4   Max: 30.1
Current: 19.8
-12.4
30.1
ROA (%) 13.6
BIIB's ROA (%) is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. BIIB: 13.6 )
BIIB' s 10-Year ROA (%) Range
Min: -9.2   Max: 23.3
Current: 13.6
-9.2
23.3
ROC (Joel Greenblatt) (%) 89.40
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. BIIB: 89.40 )
BIIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -47   Max: 102
Current: 89.4
-47
102
Revenue Growth (%) 11.1
BIIB's Revenue Growth (%) is ranked higher than
82% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. BIIB: 11.1 )
BIIB' s 10-Year Revenue Growth (%) Range
Min: -1.9   Max: 45.6
Current: 11.1
-1.9
45.6
EBITDA Growth (%) 11.7
BIIB's EBITDA Growth (%) is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. BIIB: 11.7 )
BIIB' s 10-Year EBITDA Growth (%) Range
Min: -14.2   Max: 32.6
Current: 11.7
-14.2
32.6
EPS Growth (%) 14.5
BIIB's EPS Growth (%) is ranked higher than
90% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. BIIB: 14.5 )
BIIB' s 10-Year EPS Growth (%) Range
Min: -55.5   Max: 130.9
Current: 14.5
-55.5
130.9
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

BIIB Guru Trades in Q2 2012

Bill Frels 1,475 sh (New)
Andreas Halvorsen 3,586,445 sh (+11.54%)
RS Investment Management 16,810 sh (+1.51%)
John Hussman 1,000,000 sh (unchged)
Vanguard Health Care Fund 2,220,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 2,433 sh (-0.82%)
Jeremy Grantham 165,471 sh (-5.52%)
PRIMECAP Management 21,519,059 sh (-7.48%)
Murray Stahl 11,090 sh (-8.81%)
Jim Simons 881,400 sh (-10.02%)
Mario Gabelli 3,500 sh (-12.5%)
Chuck Royce 600 sh (-25%)
Steven Cohen 174,551 sh (-78.34%)
» More
Q3 2012

BIIB Guru Trades in Q3 2012

Ray Dalio 60,804 sh (New)
Paul Tudor Jones 2,400 sh (New)
Joel Greenblatt 2,172 sh (New)
Jeremy Grantham 166,133 sh (+0.4%)
Jim Simons 882,500 sh (+0.12%)
Murray Stahl 10,990 sh (-0.9%)
PRIMECAP Management 21,135,113 sh (-1.78%)
Bill Frels 1,400 sh (-5.08%)
Steven Cohen 165,066 sh (-5.43%)
Pioneer Investments 2,218 sh (-8.84%)
RS Investment Management 15,210 sh (-9.52%)
Chuck Royce 500 sh (-16.67%)
Mario Gabelli 2,900 sh (-17.14%)
Vanguard Health Care Fund 1,570,000 sh (-29.28%)
Andreas Halvorsen 2,000,023 sh (-44.23%)
John Hussman 500,000 sh (-50%)
» More
Q4 2012

BIIB Guru Trades in Q4 2012

RS Investment Management 31,310 sh (+105.85%)
Jim Simons 1,670,961 sh (+89.34%)
Andreas Halvorsen 2,725,961 sh (+36.3%)
Bill Frels 1,682 sh (+20.14%)
Mario Gabelli 3,030 sh (+4.48%)
Jeremy Grantham 142,300 sh (unchged)
John Hussman 500,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
PRIMECAP Management 20,849,653 sh (-1.35%)
Vanguard Health Care Fund 1,520,000 sh (-3.18%)
Pioneer Investments 2,057 sh (-7.26%)
Murray Stahl 8,990 sh (-18.2%)
Steven Cohen 110,825 sh (-32.86%)
Ray Dalio 18,260 sh (-69.97%)
» More
Q1 2013

BIIB Guru Trades in Q1 2013

Frank Sands 3,578,308 sh (New)
Paul Tudor Jones 77,300 sh (New)
Ray Dalio 49,712 sh (+172.25%)
Jeremy Grantham 153,515 sh (+7.88%)
Bill Frels 1,682 sh (unchged)
Vanguard Health Care Fund 1,520,000 sh (unchged)
Murray Stahl 8,970 sh (-0.22%)
RS Investment Management 31,180 sh (-0.42%)
Jim Simons 1,618,161 sh (-3.16%)
PRIMECAP Management 19,207,553 sh (-7.88%)
Pioneer Investments 1,827 sh (-11.18%)
Mario Gabelli 2,430 sh (-19.8%)
Steven Cohen 81,653 sh (-26.32%)
John Hussman 258,000 sh (-48.4%)
Andreas Halvorsen 1,286,835 sh (-52.79%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Frank Sands 2013-03-31 New Buy2.4%$142.82 - $192.618 $ 226.8541%3578308
Andreas Halvorsen 2013-03-31 Reduce -52.79%1.48%$142.82 - $192.618 $ 226.8541%1286835
John Hussman 2013-03-31 Reduce -48.4%0.92%$142.82 - $192.618 $ 226.8541%258000
Ray Dalio 2013-03-31 Add 172.25%0.06%$142.82 - $192.618 $ 226.8541%49712
Andreas Halvorsen 2012-12-31 Add 36.3%0.75%$135.61 - $154.22 $ 226.8554%2725961
Ray Dalio 2012-12-31 Reduce -69.97%0.08%$135.61 - $154.22 $ 226.8554%18260
Joel Greenblatt 2012-12-31 Sold Out 0.02%$135.61 - $154.22 $ 226.8554%0
Andreas Halvorsen 2012-09-30 Reduce -44.23%1.86%$139.09 - $156.06 $ 226.8555%2000023
John Hussman 2012-09-30 Reduce -50%1.35%$139.09 - $156.06 $ 226.8555%500000
Vanguard Health Care Fund 2012-09-30 Reduce -29.28%0.44%$139.09 - $156.06 $ 226.8555%1570000
Ray Dalio 2012-09-30 New Buy0.12%$139.09 - $156.06 $ 226.8555%60804
Joel Greenblatt 2012-09-30 New Buy0.02%$139.09 - $156.06 $ 226.8555%2172
Andreas Halvorsen 2012-06-30 Add 11.54%0.43%$125.29 - $143.17 $ 226.8571%3586445
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Biogen Idec Inc

Edward Owens’ Vanguard Health Care Fund Does More Shedding Than Adding in Third Quarter
November 1, 2012
Edward Owens - Edward Owens’ Vanguard Health Care Fund Does More Shedding Than Adding In Third Quarter
Pennsylvania-based Vanguard Health Care Fund has reduced its stake of five companies out of the seven total transactions it reported recently for its third quarter portfolio update. Read more...
52-Week High Guru Stocks: BIIB, GE, BDX, IR, PFE
September 24, 2012
According to GuruFocus' list of 52-week highs, these Guru stocks have reached their 52-week highs. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 36.00
BIIB's P/E(ttm) is ranked higher than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 20.85 vs. BIIB: 36.00 )
BIIB' s 10-Year P/E(ttm) Range
Min: 11.73   Max: 1737.8
Current: 36
11.73
1737.8
P/B 7.70
BIIB's P/B is ranked lower than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BIIB: 7.70 )
BIIB' s 10-Year P/B Range
Min: 1.27   Max: 30.98
Current: 7.7
1.27
30.98
P/S 9.61
BIIB's P/S is ranked higher than
50% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. BIIB: 9.61 )
BIIB' s 10-Year P/S Range
Min: 2.8   Max: 43.71
Current: 9.61
2.8
43.71
PFCF 33.41
BIIB's PFCF is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. BIIB: 33.41 )
BIIB' s 10-Year PFCF Range
Min: 11.22   Max: 2328.5
Current: 33.41
11.22
2328.5
EV-to-EBIT 27.23
BIIB's EV-to-EBIT is ranked higher than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. BIIB: 27.23 )
BIIB' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 274.2
Current: 27.23
8.3
274.2
PEG 2.52
BIIB's PEG is ranked higher than
99% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.35 vs. BIIB: 2.52 )
BIIB' s 10-Year PEG Range
Min: 0.06   Max: 25.22
Current: 2.52
0.06
25.22
Shiller P/E 87.47
BIIB's Shiller P/E is ranked higher than
76% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. BIIB: 87.47 )
BIIB' s 10-Year Shiller P/E Range
Min: 32.5   Max: 756.57
Current: 87.47
32.5
756.57

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 57.3
BIIB's Price/Net Current Asset Value is ranked higher than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. BIIB: 57.3 )
BIIB' s 10-Year Price/Net Current Asset Value Range
Min: 13.7   Max: 274.7
Current: 57.3
13.7
274.7
Price/Tangible Book 13
BIIB's Price/Tangible Book is ranked higher than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. BIIB: 13 )
BIIB' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 26.8
Current: 13
2.9
26.8
Price/DCF (Projected) 3.8
BIIB's Price/DCF (Projected) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. BIIB: 3.8 )
BIIB' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 14.1
Current: 3.8
1.1
14.1
Price/Median PS Value 1.2
BIIB's Price/Median PS Value is ranked higher than
79% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. BIIB: 1.2 )
BIIB' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 3.9
Current: 1.2
0.4
3.9
Price/Peter Lynch Fair Value 1.5
BIIB's Price/Peter Lynch Fair Value is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. BIIB: 1.5 )
BIIB' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 20.5
Current: 1.5
0.6
20.5
Price/Graham Number 4.7
BIIB's Price/Graham Number is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. BIIB: 4.7 )
BIIB' s 10-Year Price/Graham Number Range
Min: 1.8   Max: 19.7
Current: 4.7
1.8
19.7
Earnings Yield (Greenblatt) 3.70
BIIB's Earnings Yield (Greenblatt) is ranked higher than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. BIIB: 3.70 )
BIIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12
Current: 3.7
0.4
12
Forward Rate of Return (Yacktman) 1.33
BIIB's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. BIIB: 1.33 )
BIIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 354.1
Current: 1.33
1
354.1

Business Description

Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1997. In 2003, the Company acquired Biogen, Inc. and changed its corporate name from IDEC Pharmaceuticals Corporation to Biogen Idec Inc. The Company is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's marketed products include AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. AVONEX is one of the most prescribed treatments in the world for relapsing forms of MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. TYSABRI has advanced the treatment of MS patients with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. FUMADERM is approved for the treatment of severe psoriasis in Germany. Psoriasis is a skin disease in which cells build up on the skin surface and form scales and red patches. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care "fraud and abuse," including anti-kickback laws and false claims laws.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY
Traded in other countries:IDP.Germany
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
52-Week High Guru Stocks: BIIB, GE, BDX, IR, PFE Sep 24 2012 
Weekly Top Insider Sells: GOOG, FIS, ORCL, and BIIB Aug 06 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
Bearish John Hussman Sold Heavily in the First Quarter; New Portfolio Update May 02 2012 
Maybe Diversification Is Not All It's Cracked Up to Be Apr 19 2012 
Questcor: A Highly Shorted Stock To Watch This Year Apr 14 2012 
PRIMECAP Odyssey Funds Letter to Shareholders, Discusses Health Care, IT Jan 10 2012 
5 Pharmaceutical Stocks to Buy, 1 to Avoid Dec 19 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial